Overview

Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
A single intravenous injection of zileuton (150 or 300 mg) will be administered to patients with stable asthma. The goals will be to determine if zileuton i.v. can produce a rapid increase in FEV1/PEFR and when this effect can be seen. The safety of this route of administration of zileuton will also be studied. PK will be obtained in a population based method.
Phase:
Phase 2
Details
Lead Sponsor:
Critical Therapeutics
Treatments:
Hydroxyurea
Zileuton